JBIO logo

JBIO Jade Biosciences, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$15.31
+0.25 (+1.66%)

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jad…

Market Cap: $1.06Bjadebiosciences.com

Price

No data yet.

Social Signal Score

70
5d
—
30d
70
2 mentions
—
60d
70
4 mentions
—
90d
70
5 mentions
—
news: 5

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$47.2+208.3%
Low $41Median $47High $55
Current Consensus

Revenue

$0.00
$0.00
Sep 2023Sep 2026

Analyst Estimates

FY2025
$-2.88
$-3.59–$-2.32
5 analysts
FY2026
$-2.51
$-2.80–$-2.25
4 analysts
FY2027
$-2.53
$-2.87–$-2.01
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Tom Frohlich
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
1.45
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
19.66
jadebiosciences.com